I.

Mission statements
“Advance medical science to help people live healthier lives”
Caring is central to work that Abbott do and defines their responsibility to those they serve.
• Advanced leading – edge science and technologies that hold the potential for
significant improvements to health and to the practice of health care
• Value the diversity direction
• Focus on exceptional performance
• Strive to earn the trust of those served
• Sustain success: innovative and a desire to make a meaningful difference in all
that they do

II. History
 1923: The development of Butyl, a butyl alcohol – based anesthetic, marks the beginning
of Abbott’s long, productive, and ground breaking involvement in anesthesia.
 1932: Entered nutrition field, became the leader in the new field of Vitamin, and the
leadership in the nutrition business
 1940s and 1950s: involved aggressively in the medication treatment
 1980s: aggressively performed the innovation strategy, introduced many kinds of drugs,
nutrition, and system for healthcare
• The TDX therapeutic drug monitoring system
• Depakote – New treatment for epilepsy
• Won U.S approval to market the world’s diagnostic test for AIDS
• New drug for hypertension treatment
• IMx immunoassay system – one of the best-selling products in Abbott Labs’
history
 1990s: continued the innovation strategy:
• New macrolide antibiotic
• New labor saving diagnostic system
• One of the first drugs for AIDS treatment
• Strategic acquisition: Sequoia – Turners Corp., Medi Sense, Inc.
 2000s: strongly performed the strategic acquisitions:
• Acquired: BASF, BYSIS, Therasense, EAS, ….
• Launched: next generation treatment for HIV, HUMIRA – rheumatoid arthritis
(the most successful product ever)
Following the history, we can see that the company has strived to accomplish its
missions: strongly advanced medical science, widened business lines (through
acquisitions and innovation). Besides, many products have become the most successful
products in the pharmaceutical industry. That achievement has partially proved for the
company’s commitment to the customers’ value.
III. SWOT analysis
Strengths

• Global presence
• Impressive growth forecast for Humira across a wide range of autoimmune
disorders
 • Robust lipid management portfolio supported by a range of pipeline programs
• Strong record of lifecycle management crucial in view of forthcoming patent
expires
• Innovation leader in the industry

Weaknesses

• Upcoming patent expires

• Narrow phase III pipeline, with little in the way of explosive launch opportunities
• Late-stage pipeline currently offers limited expansion beyond existing therapeutic
positions

Opportunities

• License agreements
• Launch of Flutiform
• Positive outlook for diagnostics market

Threats

• Unprecedented generic erosion exacerbated by ineffective product lifecycle

launches
• Government regulation
• Industry consolidation